Are you Dr. Reding?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 44 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
420 Delaware St Se
Mmc 480
Minneapolis, MN 55455Phone+1 612-625-1104- Is this information wrong?
Summary
- Dr. Mark Reding, MD is an oncologist in Minneapolis, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with M Health Fairview University of Minnesota Medical Center, M Health Fairview Southdale Hospital, and M Health Fairview Ridges Hospital.
Education & Training
- University of MinnesotaFellowship, Hematology and Medical Oncology, 1996 - 1999
- University of MinnesotaResidency, Internal Medicine, 1992 - 1995
- University of Minnesota Medical SchoolClass of 1992
Certifications & Licensure
- MN State Medical License 1994 - 2024
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Inhibitor Development in Patients With Hemophilia A Undergoing Surgery Start of enrollment: 2011 Nov 01
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B Start of enrollment: 2013 Feb 11
- Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsBuilding the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people wit...Duc Q Tran, Craig C Benson, Judith A Boice, Meera Chitlur, Amy L Dunn, Miguel A Escobar, Kalpna Gupta, Jill M Johnsen, James Jorgenson, Scott D Martin, Suzanne Martin,...> ;Expert Review of Hematology. 2023 Mar 1
- 26 citationsTwo-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou, Margareth C Ozelo, Gili Kenet, Flora Peyvandi, Michael Wang, Bella Madan, ...> ;The New England Journal of Medicine. 2023 Feb 23
- 1 citationsEfficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities:analysis from the PROTECT VIII study.Mark T Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth, Ced...> ;Therapeutic Advances in Hematology. 2023 Jan 1
- Join now to see all
Press Mentions
- Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual SummitJune 15th, 2020
- FDA Approves JiviAugust 31st, 2018
Hospital Affiliations
- M Health Fairview University of Minnesota Medical CenterMinneapolis, Minnesota
- M Health Fairview Ridges HospitalBurnsville, Minnesota
- M Health Fairview Southdale HospitalMinneapolis, Minnesota